Regarding “Stenting for femoropopliteal lesions”  by Schillinger, Martin & Minar, Erich
would argue that such a life expectancy is certainly long enough
not to simply disregard the radiocephalic fistula.
Andy Robert Weale, MRCS
Surgery, Southmead Hospital
Bristol, Avon, United Kingdom
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Regarding “Stenting for femoropopliteal lesions”
We have read with interest the article by Mwipatayi et al1 on
the contemporary topic of femoropopliteal stenting. Unfortu-
nately, the authors’ conclusion that stent placement for treatment
of femoropopliteal disease does not increase patency at 1 year
compared with balloon angioplasty alone is flawed by several
unacceptable limitations of this meta-analysis.
Clinical heterogeneity of the included studies is the most
relevant drawback: First, different types of stents (balloon-
expanding stainless steel stents, self-expanding Elgiloy stents, self-
expanding Nitinol stents, and polytetrafluoroethylene-covered stent
grafts) were included in the analysis. Each of these devices has
fundamentally differential characteristics, indications, and out-
comes, and therefore cannot be summarized as one category.2
Second, seven prospective randomized studies were mixed with
the results of a retrospective and purely observational study. Par-
ticularly, the latter study was of extremely poor quality without
standardized follow-up intervals (follow-up ranged from 1 to 72
months). Third, clinical characteristics of patients treated within
the studies were highly variable: Balloon-expanding stents can be
used for only very short lesions (spot stenting), whereas stent grafts
and self-expanding stents are implanted for longer lesions. Because
of this selection bias, it is impossible to assess whether stents may
have beneficial effects in certain predefined subgroups (eg, patients
with long lesions or total occlusions). Fourth, treatment strategies
within the different trials were not consistent: six randomized
studies including short lesions compared primary stenting vs bal-
loon angioplasty alone. In contrast, one study that also included
longer lesions compared primary stenting vs balloon angioplasty
with optional secondary stenting.3
In Table 1 restenosis and patency rates of the ABSOLUTE
trial3 at 12 months are mixed up (the table reports 63% patency
rate, which should read 37%). This overestimation may have sig-
nificantly influenced the pooled risk estimates.
Addressing the issue of stent fractures, six of the eight studies
did not systematically assess stent fractures; therefore, this end
point should not be reported.
Finally, a cut off for including studies published later than the
year 2000 is by no scientific means justified. A major change in
stent technology was seen in 2004 and 2005 when the first
promising data on Nitinol stents were reported. From our point of
view, a clinically reasonable meta-analysis should include only data
from randomized controlled trials comparing Nitinol stents vs
balloon angioplasty, that is, findings from the ABSOLUTE,3
FAST,4 and RESILIENT trials.
Martin Schillinger, MD
Erich Minar, MD
Department of Angiology
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Reply
The drawbacks of our study were addressed in the discussion
portion of our paper.
1. We were unable to acquire missing data from the authors of
included studies. The clinical heterogeneity of the included
studies was a relevant drawback because those studies were
conducted by different authors; these authors may not have
included data according to the Society for Vascular Surgery/
International Society for Cardiovascular Surgery (SVS/ISCS)
standard of reporting, thus affecting the results of the meta-
analysis.
2. A sensitivity analysis was performed that excluded studies that
might influence the final result. It did not change the findings of
our meta-analysis.
3. In the Design/Methods section of our paper, we clearly defined
re-stenosis and primary patency. Re-stenosis and patency rates
were not mixed in Table 1. Unfortunately, reporting inconsis-
tencies occurred in all studies. Some authors included restenosis
rate and others reported primary patency.
4. We agree that the issue of stent fractures cannot be reported as
an end point: We did, however, include the results of the few
studies that reported stent fractures because we have reported
our own experience in another area (carotid stenting).
5. Data for this study were collected from September 2000 and
January 2007, and Absolute and Fast were included. The
Resilient results were not available at that time. We were
amenable to the inclusion of studies that did use new stent
technology.
JOURNAL OF VASCULAR SURGERY
July 2008252 Letters to the Editor
